| Trial ID: | L1156 |
| Source ID: | NCT01263028
|
| Associated Drug: |
Ergocalciferol Supplementation
|
| Title: |
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
|
| Acronym: |
EASY
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01263028/results
|
| Conditions: |
Chronic Kidney Disease Stages 3-5
|
| Interventions: |
DRUG: Ergocalciferol supplementation
|
| Outcome Measures: |
Primary: Evaluate if Ergocalciferol Supplementation to Achieve 25-hydroxy Vitamin D Levels > 40ng/ml Will Decrease Erythropoietin Requirements, 24 Weeks | Secondary: Change in Inflammatory Markers, 24 Weeks|Change in Calcium, Phosphorous,Calcium x Phosphorous Product, and Parathyroid Hormone Levels, 24 Weeks|Change in Iron Supplementation, 24 Weeks|Change in Erythropoietin Adjusted for Change in Inflammatory Markers, Vitamin D Levels and Clinical and Demographic Confounders, 24 Weeks
|
| Sponsor/Collaborators: |
Sponsor: Kaiser Permanente
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
6
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-08
|
| Completion Date: |
2011-09
|
| Results First Posted: |
2012-09-20
|
| Last Update Posted: |
2015-03-30
|
| Locations: |
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, 90027, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01263028
|
